Related Experiment Video
Updated: Nov 2, 2025
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
Current and future drug combination strategies based on programmed death-1/programmed death-ligand 1 inhibitors in
Ying Cheng1, Hui Li2, Liang Zhang1
1Department of Thoracic Oncology, Jilin Cancer Hospital, Changchun, Jilin 130012, China.
Abstract:
In recent years, immune checkpoint inhibitors (ICIs) have made breakthroughs in the field of lung cancer and have become a focal point for research. Programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor monotherapy was the first to break the treatment pattern for non-small cell lung cancer (NSCLC). However, owing to the limited benefit of ICI monotherapy at the population level and its hyper-progressive phenomenon, it may not meet clinical needs. To expand the beneficial range of immunotherapy and improve its efficacy, several research strategies have adopted the use of combination immunotherapy. At present, multiple strategies, such as PD-1/PD-L1 inhibitors combined with chemotherapy, anti-angiogenic therapy, cytotoxic T-lymphocyte-associated protein 4 inhibitors, and radiotherapy, as well as combined treatment with new target drugs, have been evaluated for clinical practice. To further understand the current status and future development direction of immunotherapy, herein, we review the recent progress of ICI combination therapies for NSCLC.
Insights
Immune checkpoint inhibitors (ICIs) show promise in lung cancer but have limitations. Combination immunotherapy strategies are being explored to improve efficacy and expand benefits for non-small cell lung cancer (NSCLC) patients.
Area of Science:
- Oncology
- Immunotherapy
- Pulmonology
Background:
- Immune checkpoint inhibitors (ICIs) have revolutionized lung cancer treatment, particularly for non-small cell lung cancer (NSCLC).
- Monotherapy with programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitors has shown success but has limitations, including restricted population benefits and hyperprogressive disease.
- These limitations necessitate the exploration of novel therapeutic strategies to enhance treatment outcomes.
Purpose of the Study:
- To review the current progress and future directions of immune checkpoint inhibitor (ICI) combination therapies in non-small cell lung cancer (NSCLC).
- To provide an overview of various combination strategies being investigated to improve immunotherapy efficacy.
- To highlight the evolving landscape of lung cancer treatment through combination approaches.
Main Methods:
- Review of recent clinical studies and research on ICI combination therapies for NSCLC.
- Analysis of different combination strategies, including chemotherapy, anti-angiogenic therapy, and other targeted agents.
- Synthesis of current data on the efficacy and application of these combined treatments.
Main Results:
- Combination immunotherapies are being actively evaluated to overcome the limitations of monotherapy.
- Strategies include combining PD-1/PD-L1 inhibitors with chemotherapy, anti-angiogenic agents, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors, and radiotherapy.
- Emerging combinations with novel targeted drugs are also under investigation.
Conclusions:
- Combination immunotherapy holds significant potential to expand the benefits of immunotherapy in NSCLC.
- Further research and clinical evaluation are crucial to optimize these combination strategies.
- These advancements aim to improve treatment efficacy and address unmet clinical needs in advanced lung cancer.
More Related Videos
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy